Long-term survival of extremely advanced prostate cancer patients diagnosed with prostate-specific antigen over 500 ng/ml.

导出 LinkOut

翻译打印收藏纠错

第一作者： Toru,Sugihara

第一单位： Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA ezy04707@nifty.com.

作者： Toru,Sugihara ^[1] ; Changhong,Yu ^[2] ; Michael W,Kattan ^[2] ; Hideo,Yasunaga ^[3] ; Hiroyuki,Ihara ^[4] ; Mizuki,Onozawa ^[5] ; Shiro,Hinotsu ^[6] ; Hideyuki,Akaza ^[7]

作者单位： Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA ezy04707@nifty.com. ^[1] Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA. ^[2] Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo. ^[3] Department of Urology, Shintoshi Hospital, Iwata. ^[4] Department of Urology, Tokyo-kita Medical Center, Tokyo. ^[5] Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama. ^[6] Department of Strategic Investigation on Comprehensive Cancer Network, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. ^[7]

关键词 androgen antagonists neoplasm metastasis prostate neoplasms prostate-specific antigen survival analysis